Considerable efforts have been made over the years to improve the estimates presented in the World Drug Report, which rely, to a large extent, on information submitted by Member States through the Annual Reports Questionnaire (ARQ). Nonetheless, challenges remain in making such estimates because of data gaps and the varying quality of the available data. One major problem is the irregularity and incompleteness in ARQ reporting by Member States. Irregular reporting may result in absence of data for some years, and may influence the reported trend in a given year. Secondly, submitted questionnaires are not always complete or comprehensive, and thirdly, much of the data collected are subject to limitations and biases. These issues affect the reliability, quality and comparability of the information received.

**Sources of information**

Under the International Drug Conventions, Member States are formally required to provide national drug control related information annually to the ‘Secretary General’ of the United Nations (i.e. the Secretariat of UNODC). For this purpose, the Commission on Narcotic Drugs developed the Annual Reports Questionnaire (ARQ) that is sent to Member States for responses each calendar year.

The World Drug Report 2015 is based primarily on data obtained from the ARQ returned by Governments to UNODC up to 31 December 2014. The data collected in the current ARQ normally refer to the drug situation in 2013. UNODC sent out the questionnaire to 192 Member States, as well as 15 territories. In response, up to 31 December, 2014 UNODC had received 98 replies to its questionnaire on the “Extent and patterns of and trends in drug use (ARQ Part III)” and 100 replies to Part IV on “Extent and patterns and trends in drug crop cultivation, manufacturing and trafficking”. The best coverage was from Member States in Europe where 87 per cent of the countries responded, in Asia 61 per cent and in the Americas 36 per cent of the countries filled in the ARQ.

In the case of Africa, 22 per cent of the Member States and in the Oceania region, only three out of the 14 countries responded to the Annual Report Questionnaire. Member States’ responses to the ARQ are shown on the maps which follow.

In general, the quantity of information provided on illicit drug supply is significantly better than that of information provided on drug demand. Analysis of responses to Part IV of the ARQ revealed that 78% of them were ‘substantially’ completed compared to 61% of Part III. (ARQ which were more than 50% completed were classified as having been ‘substantially filled in’; less than 50% completion is classified as having been ‘partially filled in’).

In order to analyse the extent to which Member States provided information, a number of key questions in the ARQ were identified:

- For Part III, on the extent and patterns and trends of drug abuse, the key questions used for the analysis referred to: trends in drug use, for which 73% of the Member States and territories returning the ARQ provided information; prevalence of different drugs among the general population for which 55% of the Member States responded; for prevalence of drug use among youth 47% responded; and for treatment demand 82% responded. The overall response rate of completion was 61% for the countries which submitted Part III to UNODC, however this analysis does not take into account the completeness or quality of the information provided in response to each of the areas mentioned.

- For Part IV, on the extent and patterns and trends in drug crop cultivation, manufacturing and trafficking, the analysis included replies to the questions on: the quantities seized, for which 98% of the Member States returning the ARQ provided the information; on trafficking of illicit drugs, for which 84% of the Member States provided responses; on prices and purity, for which 80% of the Member States responded, and on persons brought into formal contact with the police and/or the criminal justice system in connection with drug-related offences, which 82% of the Member States provided information. The overall analysis of these data revealed that 78% of the Part IV responses were “substantially” completed. However this analysis does not take into account the completeness of responses of the quantity of information provided in each of sections mentioned.

Information provided by Member States in the ARQ form the basis for the estimates and trend analysis provided in the World Drug Report. Often, this information and data is not sufficient to provide an accurate or comprehensive picture of the world’s drug markets. When necessary and where available, the data from the ARQ are thus supplemented with data from other sources.

As in previous years, seizure data made available to UNODC via the ARQ was complemented primarily with data from other government sources, such as official national publications, data provided to UNODC by the Heads of National Law Enforcement Agencies (HONLEA) at their regional meetings. and data published by international and regional organisations such as Interpol/ICPO, World Customs Organization, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the Inter-American Drug Abuse Control Commission (CICAD). Price data for Europe were complemented with data from Europol. Precursor data presented are mainly those collected by the International Narcotics Control Board (INCB). Demand related information was obtained.
Member states that provided annual reports questionnaire drug demand data for 2013

ARQ Part III
- Substantially
- Partially
- Blank
- No data available or no ARQ received

Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

Member states that provided annual reports questionnaire drug supply data for 2013

ARQ Part IV
- Substantially
- Partially
- Blank
- No data available or no ARQ received

Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
through a number of additional sources, including the national assessments of the drug situation supported by UNODC, the drug control agencies participating in the UNODC’s ‘Drug Abuse Information Network for Asia and the Pacific’ (DAINAP), as well as various national and regional epidemiological networks such as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) or the Inter-American Drug Abuse Control Commission (CICAD). Reports published by National governments and academic research published in the scientific literature were also used as additional sources of information. This type of supplementary information is useful and necessary as long as Member States lack the monitoring systems necessary to produce reliable, comprehensive and internationally comparable data.

To this end, UNODC encourages and supports the improvement of national monitoring systems. Major progress has been made in the area of illicit crop monitoring over the last few years in some of the countries that have major illicit crop cultivations. In close cooperation with UNODC and with the support of major donors – these countries have developed impressive monitoring systems designed to identify the extent of, and trends in, the cultivation of narcotic plants. These data form a fundamental basis for trend analysis of illicit crop cultivation and drug production presented in the World Drug Report.

There remain significant data limitations on the demand side. Despite commendable progress made in a number of Member States, in the area of prevalence estimates for example, far more remains to be done to provide a truly reliable basis for trend and policy analysis and needs assessments. The work currently being done on the World Drug Report 2015 provides yet another opportunity to emphasize the global need for improving the evidence base available to the policy makers and programme planners.

Data on drug use and health consequences

Overview

UNODC estimates of the extent of illicit drug use in the world have been published periodically since 1997. Assessing the extent of drug use (the prevalence and estimates of the number of drug users) is a particularly difficult undertaking because it involves in most settings measuring the size of a ‘hidden’ population. Regional and global estimates are reported with ranges to reflect the information gaps. The level of confidence expressed in the estimates varies across regions and drug types.

A global estimate of the level of use of a specific drug involves the following steps:

1. Identification and analysis of appropriate sources (starting from the ARQ);
2. Identification of key benchmark figures for the level of drug use in all countries where data are available (annual prevalence of drug use among the general population aged 15-64) which then serve as ‘anchor points’ for subsequent calculations;
3. ‘Standardization’ of existing data if reported with a different reference population than the one used for the World Drug Report (for example, from age group 12 and above to a standard age group of 15-64);
4. Adjustments of national indicators to estimate an annual prevalence rate if such a rate is not available (for example, by using the lifetime prevalence or current use rates; or lifetime or annual prevalence rates among the youth population). This includes the identification of adjustment factors based on information from countries in the region with similar cultural, social and economic situations where applicable;
5. Imputation for countries where data are not available, based on data from countries in the same subregion. Ranges are calculated by considering the 10th and 90th percentile of the subregional distribution;
6. Extrapolation of available results for a subregion were calculated only for subregions where prevalence estimates for at least two countries covering at least 20% of the population were available. If, due to a lack of data, subregional estimates were not extrapolated, a regional calculation was extrapolated based on the 10th and 90th percentile of the distribution of the data available from countries in the region.
7. Aggregation of subregional estimates rolled-up into regional results to arrive at global estimates.

For countries that did not submit information through the ARQ, or in cases where the data were older than 10 years, other sources were identified, where available. In nearly all cases, these were government sources. Many estimates needed to be adjusted to improve comparability (see below).

In cases of estimates referring to previous years, the prevalence rates were left unchanged and applied to new population estimates for the year 2013. Currently, only a few countries measure drug prevalence among the general population on an annual basis. The remaining countries that regularly measure it - typically the more economically developed - do so usually every three to five years. Therefore, caution should be used when interpreting any change in national, regional or even global prevalence figures, as changes may in part reflect newer reports from countries, at times with changed methodology, or the exclusion of older reports, rather than actual changes in prevalence of a drug type.

Detailed information on drug use is available from countries in North America, a large number of countries in Europe, a number of countries in South America, the two large countries in Oceania and a limited number of countries in Asia and Africa. One key problem in national data is the level of accuracy, which varies strongly from country to country. Not all estimates are based on sound epide-
Drug-related morbidity (prevalence of HIV, hepatitis B virus and hepatitis C virus among drug users);  
6. Drug-related mortality (deaths attributable to drug use).

Efforts have been made to present the overall drug situation from countries and regions based on these key epidemiological indicators.

The use of annual prevalence is a compromise between lifetime prevalence data (drug use at least once in a lifetime) and data on current use (drug use at least once over the past month). The annual prevalence rate is usually shown as a percentage of the youth and adult population. The definitions of the age groups vary, however, from country to country. Given a highly skewed distribution of drug use among the different age cohorts in most countries, differences in the age groups can lead to substantially diverging results.

Applying different methodologies may also yield diverging results for the same country. In such cases, the sources were analysed in-depth and priority was given to the most recent data and to the methodological approaches that are considered to produce the best results. For example, it is generally accepted that nationally representative household surveys are reasonably good approaches to estimating cannabis, ATS or cocaine use among the general population, at least in countries where there are no adverse consequences for admitting illicit drug use. Thus, household survey results were usually given priority over other sources of prevalence estimates.

When it comes to the use of opiates (opium, heroin, and other illicit opiates), injecting drug use, or the use of cocaine and ATS among regular or dependent users, annual prevalence data derived from national household surveys tend to grossly under-estimate such use, because heroin or other problem drug users often tend to be marginalized or less socially integrated, and may not be identified as living in a ‘typical’ household (they may be on the streets, homeless or institutionalized). Therefore, a number of ‘indirect’ methods have been developed to provide estimates for this group of drug users, including benchmark and multiplier methods (benchmark data may include treatment demand, police registration or arrest data, data on HIV infections, other services utilization by problem drug users or mortality data), capture-recapture methods and multivariate indicators. In countries where there was evidence that the primary ‘problem drug’ was opiates, and an indirect estimate existed for ‘problem drug use’ or

Indicators used

The most widely used indicator at the global level is the annual prevalence rate: the number of people who have consumed an illicit drug at least once in the last twelve months prior to the study. Annual prevalence has been adopted by UNODC as one of key indicators to measure the extent of drug use. It is also part of the Lisbon Consensus on core epidemiological indicators of drug use which has been endorsed by the Commission on Narcotic Drugs. The key epidemiological indicators of drug use are:

1. Drug consumption among the general population (prevalence and incidence);
2. Drug consumption among the youth population (prevalence and incidence);
3. High-risk drug use (number of injecting drug users and the proportion engaged in high-risk behaviour, number of daily drug users);
4. Utilization of services for drug problems (treatment demand);
5. Drug-related morbidity (prevalence of HIV, hepatitis B virus and hepatitis C virus among drug users);
6. Drug-related mortality (deaths attributable to drug use).

Efforts have been made to present the overall drug situation from countries and regions based on these key epidemiological indicators.

The use of annual prevalence is a compromise between lifetime prevalence data (drug use at least once in a lifetime) and data on current use (drug use at least once over the past month). The annual prevalence rate is usually shown as a percentage of the youth and adult population. The definitions of the age groups vary, however, from country to country. Given a highly skewed distribution of drug use among the different age cohorts in most countries, differences in the age groups can lead to substantially diverging results.

Applying different methodologies may also yield diverging results for the same country. In such cases, the sources were analysed in-depth and priority was given to the most recent data and to the methodological approaches that are considered to produce the best results. For example, it is generally accepted that nationally representative household surveys are reasonably good approaches to estimating cannabis, ATS or cocaine use among the general population, at least in countries where there are no adverse consequences for admitting illicit drug use. Thus, household survey results were usually given priority over other sources of prevalence estimates.

When it comes to the use of opiates (opium, heroin, and other illicit opiates), injecting drug use, or the use of cocaine and ATS among regular or dependent users, annual prevalence data derived from national household surveys tend to grossly under-estimate such use, because heroin or other problem drug users often tend to be marginalized or less socially integrated, and may not be identified as living in a ‘typical’ household (they may be on the streets, homeless or institutionalized). Therefore, a number of ‘indirect’ methods have been developed to provide estimates for this group of drug users, including benchmark and multiplier methods (benchmark data may include treatment demand, police registration or arrest data, data on HIV infections, other services utilization by problem drug users or mortality data), capture-recapture methods and multivariate indicators. In countries where there was evidence that the primary ‘problem drug’ was opiates, and an indirect estimate existed for ‘problem drug use’ or
injecting drug use, this was preferred over household survey estimates of heroin use. Therefore for most of the countries, prevalence of opioid or opiates use reported refers to the extent of use of these substances measured through indirect methods.

For other drug types, priority was given to annual prevalence data found by means of household surveys. In order to generate comparable results for all countries, wherever needed, the reported data was extrapolated to annual prevalence rates and/or adjusted for the preferred age group of 15-64 for the general population.

Extrapolation methods used

Adjustment for differences in age groups

Member States are increasingly using the 15-64 age group, though other groups are used as well. Where the age groups reported by Member States did not differ significantly from 15-64, they were presented as reported, and the age group specified. Where studies were based on significantly different age groups, results were typically adjusted. A number of countries reported prevalence rates for the age groups 15+ or 18+. In these cases, it was generally assumed that there was no significant drug use above the age of 64. The number of drug users based on the population age 15+ (or age 18+) was thus shown as a proportion of the population aged 15-64.

Extrapolation of results from lifetime prevalence to annual prevalence

Some countries have conducted surveys in recent years without asking the question whether drug consumption took place over the last year. In such cases, results were extrapolated to reach annual prevalence estimates. For example, country X in West and Central Europe reported a lifetime prevalence of cocaine use of 2%. Taking data for lifetime and annual prevalence of cocaine use in countries of West and Central Europe, it can be shown that there is a strong positive correlation between the two measures (correlation coefficient R = 0.94); that is, the higher the lifetime prevalence, the higher the annual prevalence and vice versa. Based on the resulting regression line (with annual prevalence as the dependent variable and lifetime prevalence as the independent variable) it can be estimated that a country in West and Central Europe with a lifetime prevalence of 2% is likely to have an annual prevalence of around 0.7% (see figure). Almost the same result is obtained by calculating the ratio of the unweighted average of annual prevalence rates of the West and Central European countries and the unweighted average lifetime prevalence rate (0.93/2.61 = 0.356) and multiplying this ratio with the lifetime prevalence of the country concerned (2% * 0.356 = 0.7%).

A similar approach was used to calculate the overall ratio by averaging the annual/lifetime ratios, calculated for each country. Multiplying the resulting average ratio (0.334) with the lifetime prevalence of the country concerned provides the estimate for the annual prevalence (0.387 * 2% = 0.8%). There is a close correlation observed between lifetime and annual prevalence (and an even stronger correlation between annual prevalence and monthly prevalence). Solid results (showing small potential errors) can only be expected from extrapolations done for a country in the same region. If instead of using the West and Central European average (0.387), the ratio found in the USA was used (0.17), the estimate for a country with a lifetime prevalence of cocaine use of 2% would decline to 0.3% (2% * 0.17). Such an estimate is likely to be correct for a country with a drug history similar to the USA, which has had a cocaine problem for more than two decades, as opposed to West and Central Europe, where the cocaine problem is largely a phenomenon of the last decade. Therefore, data from countries in the same subregion with similar patterns in drug use were used, wherever possible, for extrapolation purposes.

Both approaches—the regression model and the ratio model—were used to determine upper and lower uncertainty range estimates calculated at a 90% confidence interval among those aged 15-64 years in the given country. The greater the range, the larger the level of uncertainty around the estimates. The range for each country is reported in the statistical annex, where available.

Extrapolations based on school surveys

Analysis of countries which have conducted both school surveys and national household surveys shows that there is, in general, a positive correlation between the two variables, particularly for cannabis, ATS and cocaine. The correlation, however, is weaker than that of lifetime and annual prevalence or current use and annual prevalence.
among the general population. But it is stronger than the correlation between opiate use and injecting drug use and between treatment demand and extent of drug use in the general population.

These extrapolations were conducted by using the ratios between school surveys and household surveys of countries in the same region or with similar social structure where applicable. As was the case with extrapolation of results from lifetime prevalence to annual prevalence, two approaches were taken: a) the unweighted average of the ratios between school and household surveys in the comparison countries with an upper and lower uncertainty range estimate calculated at a 90% confidence interval; and b) a regression-based extrapolation, using the relationships between estimates from the other countries to predict the estimate in the country concerned, with an upper and lower uncertainty range estimate calculated at a 90% confidence interval. The final uncertainty range and best estimate are calculated using both models, where applicable.

**Extrapolations based on treatment data**

For a number of developing countries, the only drug use-related data available was drug users registered or treatment demand. In such cases, other countries in the region with a similar socio-economic structure were identified, which reported annual prevalence and treatment data. A ratio of people treated per 1,000 drug users was calculated for each country. The results from different countries were then averaged and the resulting ratio was used to extrapolate the likely number of drug users from the number of people in treatment.

**Making regional and global estimates of the number of people who use drugs and the health consequences**

For this purpose, the estimated prevalence rates of countries were applied to the population aged 15-64, as provided by the United Nations Population Division for the year 2013.

In the tables presented in the World Drug Report for regional and global estimates, totals may not add up due to rounding.

Ranges have been produced to reflect the considerable uncertainty that arises when data are either extrapolated or imputed. Ranges are provided for estimated numbers and prevalence rates in the Report. Larger ranges are reported for subregions and regions with less certainty about the likely levels of drug use — in other words, those regions for which fewer direct estimates are available, for a comparatively smaller proportion of the region’s population.

Countries with one published estimate (typically those countries with a representative household survey, or an indirect prevalence estimate that did not report ranges) did not have uncertainty estimated. This estimate is reported as the ‘best estimate’.

To account for populations in countries with no published estimate, the 10th and 90th percentile in the range of direct estimates was used to produce a lower and upper estimate. For example, there are three countries in the North Africa subregion with past year prevalence estimates for cannabis use: Algeria (0.52, a point estimate), Egypt (2.9 – 9.6) and Morocco (4.2, a point estimate). These are extrapolated to the population of the remaining three countries without prevalence data, namely the Libyan Arab Jamahiriya, Sudan and Tunisia. The 10th percentile of the lower bound of the uncertainty range (0.52, 2.9, and 4.2) is 1.0 and the 90th percentile of the upper bound (0.52, 9.6, and 4.2) is 8.5. The 1.0 and 8.5 figures are applied to the population of the remaining three countries without prevalence data to derive a subregional total lower and upper estimate of 2.2 and 6.6 per cent respectively.

In some cases, not all of a region’s subregions had estimates due to a lack of country level data. For example, past year amphetamines-group prevalence was calculated for East and South-East Asia and the Near and Middle East/South West Asia, however the remaining subregions — South Asia and Central Asia — had no estimates. To calculate an overall Asia lower and upper estimate for populations in subregions with no published estimate, all of the countries throughout the region were considered using the 10th and 90th percentile of the regional distribution. These results were then combined with those subregions where an estimate was possible. One exception was South Asia’s subregional opiate and cannabis estimates. In this case, India’s population accounts for 85% of the six countries in the subregion, but recent reliable estimates of drug use for India were not available. Instead of using all prevalence estimates for Asia (that is, estimates from the Near and Middle East to East Asia) to determine India’s contribution to the subregional uncertainty, it was determined that India’s contribution was best reflected by its neighbouring countries.

This produces conservative (wide) intervals for subregions where there is geographic variation and/or variance in existing country-level estimates; but it also reduces the likelihood that skewed estimates will have a dramatic effect on regional and global figures (since these would most likely fall outside the 10th and 90th percentile).

**Estimates of the total number of people who used illicit drugs at least once in the past year**

This year’s Report used the same approach as in the previous years. Two ranges were produced, and the lowest and highest estimate of each the approaches were taken to estimate the lower and upper ranges, respectively, of the total illicit drug using population. This estimate is obviously tentative given the limited number of countries upon which the data informing the two approaches were based. The two approaches were as follows:
**Approach 1.**

The global estimates of the number of people using each of the five drug groups in the past year were added up. Taking into account that people use more than one drug type and that these five populations overlap, the total was adjusted downward. The size of this adjustment was made based upon household surveys conducted in 15 countries globally including countries from North America (Canada, Mexico and the United States, Europe (Germany, Spain and England and Wales), Latin America (Argentina, Brazil, Plurinational State of Bolivia, Chile, Peru and Uruguay), Asia and the Pacific (Indonesia, Philippines, and Australia), which assessed all five drug types, and reported an estimate of total illicit drug use. Across these studies, the extent to which adding each population of users over estimated the total population was a median factor of 1.13. The summed total was therefore divided by 1.3

**Approach 2.**

This approach was based on the average proportion of the total drug using population that comprises cannabis users. The average proportion was obtained from household surveys conducted in the same countries as for Approach 1. Across all of these studies, the median proportion of total drug users that comprised cannabis users was 79%. The range of cannabis users at the global level was therefore divided by 0.79.

The global lower estimate was the lower of the two values obtained from the two approaches, while the upper estimate was the upper value derived from the two approaches described.

**Estimates of the number of ‘problem drug users’**

It is useful to make estimates of the number of drug users whose use is particularly problematic as this subgroup of drug users is most likely to come to the attention of health and law enforcement. Moreover, this subgroup’s drug use has been estimated to cause the main burden of disease and public order.

The number of problem drug users is typically estimated with the number of dependent drug users. Sometimes, an alternative approach is used. The EMCDDA has been using ‘injecting or long duration use of opioids, amphetamines or cocaine’ to guide country-level indirect prevalence estimation studies of problem drug use.

In this Report, as in previous years, each of the five range estimates of the number of people using each of the five drug groups was converted into a ‘heroin user equivalent’. This was calculated through the use of ‘relative risk coefficients’ (see below) derived from the UNODC Harm Index. This method enables the aggregation of results from different drugs into one reference drug.

A lower range was calculated by summing each of the five lower range estimates; the upper end of the range was calculated by summing the upper range of the five estimates.

To obtain an estimate of the number of ‘problem drug users’, these totals were multiplied by the proportion of past year heroin users in the United States National Survey on Drug Use and Health (range 53-68% over the past six years of this survey). Hence, the LOW estimate is the lower proportion (53%) multiplied by the lower estimated size of the heroin use equivalent population (29.6 million heroin user equivalents). The HIGH estimate is the higher proportion (68%) multiplied by the higher estimated size of the heroin use equivalent population (57.6 million heroin user equivalents). This gives a range of 15.7 to 39.1 million problem drug users globally.

**Estimates of the prevalence of injecting drug use, HIV and hepatitis (C and B virus) among people who inject drugs (PWID)**

**Criteria for selecting national estimates**

Besides the official UNODC, UNAIDS and WHO data collection instruments, data sources considered also included: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) country reports and the EMCDDA Statistical Bulletin; and country level estimation studies including HIV seroprevalence and behavioural surveillance.

<table>
<thead>
<tr>
<th>Relative risk coefficient</th>
<th>Treatment index</th>
<th>IDU</th>
<th>Toxicity</th>
<th>Deaths index</th>
<th>Relative risk coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Index</td>
<td>Index</td>
<td>Index</td>
<td>Index</td>
<td>(average treatment, IDU, toxicity, death)</td>
</tr>
<tr>
<td>Opiates</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cocaine</td>
<td>85.3</td>
<td>47.8</td>
<td>88</td>
<td>18.5</td>
<td>59.9</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>20.1</td>
<td>59.5</td>
<td>32</td>
<td>6.8</td>
<td>29.6</td>
</tr>
<tr>
<td>Ecstasy</td>
<td>3.8</td>
<td>6.1</td>
<td>20.7</td>
<td>1</td>
<td>7.9</td>
</tr>
<tr>
<td>Cannabis</td>
<td>9</td>
<td>0</td>
<td>1.5</td>
<td>0.6</td>
<td>2.8</td>
</tr>
</tbody>
</table>
Factors considered in selecting national data:

- Quality of methodology (i.e., classified A – D according to the table below)
- For PWID, annual prevalence in preference to lifetime injecting
- Most recent data

The study with the strongest classification of methodology was used. Where there were multiple such studies, for PWID data referring to annual prevalence was used, otherwise the most recent data was used. More recent, weaker study designs did not replace an estimate based on a superior methodology, regardless of when the study was conducted if this was within the last ten years.

For many countries there may be a number of sub-national studies conducted over a period of time. In this case, studies that were classified as ‘A’ methodologically were combined to produce a range in the national estimate.

Decision rules for selecting national estimates on HIV prevention, treatment and care services were based on the guidelines presented in Mathers et. al. (2010) Lancet article: “HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage”, who also provide a detailed web appendix to this publication.

Classification of methodology for people who inject drugs and those among them living with HIV

Data is categorized by methodology according to a slightly modified classification originally proposed in Mathers et. al. (2008) Lancet paper.

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on the prevalence of people who inject drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Indirect prevalence estimation methods e.g., capture-recapture, multiplier methods, etc.</td>
</tr>
<tr>
<td>B</td>
<td>General population survey</td>
</tr>
<tr>
<td>C</td>
<td>Treatment and other national registers of drug users</td>
</tr>
<tr>
<td>D1</td>
<td>Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>Experts’ judgment with known method of estimation (e.g. an estimate obtained through a rapid assessment)</td>
</tr>
<tr>
<td></td>
<td>Delphi method or other consensus estimate</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate with methodology unknown</td>
</tr>
</tbody>
</table>

*Data graded D2 are excluded from the dataset

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on the prevalence of people who inject drugs living with HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Seroprevalence study</td>
</tr>
<tr>
<td>A1</td>
<td>Multi-site seroprevalence study with at least two sample types (e.g. treatment or outreach sample)</td>
</tr>
<tr>
<td>A2</td>
<td>Seroprevalence study from a single sample type</td>
</tr>
<tr>
<td>B</td>
<td>Registration or notification of cases of HIV infection (e.g. from treatment services)</td>
</tr>
<tr>
<td>C</td>
<td>Prevalence study using self-reported HIV</td>
</tr>
<tr>
<td>D1</td>
<td>Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>Modelling Studies (e.g. mode of transmission models)</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate with methodology unknown</td>
</tr>
</tbody>
</table>

*Data graded D2 are excluded from the dataset

For PWID, annual prevalence in preference to lifetime injecting

The study with the strongest classification of methodology was used. Where there were multiple such studies, for PWID data referring to annual prevalence was used, otherwise the most recent data was used. More recent, weaker study designs did not replace an estimate based on a superior methodology, regardless of when the study was conducted if this was within the last ten years.

For many countries there may be a number of sub-national studies conducted over a period of time. In this case, studies that were classified as ‘A’ methodologically were combined to produce a range in the national estimate.

Decision rules for selecting national estimates on HIV prevention, treatment and care services were based on the guidelines presented in Mathers et. al. (2010) Lancet article: “HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage”, who also provide a detailed web appendix to this publication.

Classification of methodology for people who inject drugs and those among them living with HIV

Data is categorized by methodology according to a slightly modified classification originally proposed in Mathers et. al. (2008) Lancet paper.

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on the prevalence of people who inject drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Indirect prevalence estimation methods e.g., capture-recapture, multiplier methods, etc.</td>
</tr>
<tr>
<td>B</td>
<td>General population survey</td>
</tr>
<tr>
<td>C</td>
<td>Treatment and other national registers of drug users</td>
</tr>
<tr>
<td>D1</td>
<td>Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>Experts’ judgment with known method of estimation (e.g. an estimate obtained through a rapid assessment)</td>
</tr>
<tr>
<td></td>
<td>Delphi method or other consensus estimate</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate with methodology unknown</td>
</tr>
</tbody>
</table>

*Data graded D2 are excluded from the dataset

<table>
<thead>
<tr>
<th>Class</th>
<th>Data on the prevalence of people who inject drugs living with HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Seroprevalence study</td>
</tr>
<tr>
<td>A1</td>
<td>Multi-site seroprevalence study with at least two sample types (e.g. treatment or outreach sample)</td>
</tr>
<tr>
<td>A2</td>
<td>Seroprevalence study from a single sample type</td>
</tr>
<tr>
<td>B</td>
<td>Registration or notification of cases of HIV infection (e.g. from treatment services)</td>
</tr>
<tr>
<td>C</td>
<td>Prevalence study using self-reported HIV</td>
</tr>
<tr>
<td>D1</td>
<td>Official government estimate with no methodology reported</td>
</tr>
<tr>
<td></td>
<td>Modelling Studies (e.g. mode of transmission models)</td>
</tr>
<tr>
<td>D2*</td>
<td>Estimate with methodology unknown</td>
</tr>
</tbody>
</table>

*Data graded D2 are excluded from the dataset


2 This is the same as the methodology used by Mathers et. al. for the UN Reference Group estimates published in 2008.
**Ranges in estimates:** The range in the sub-regional estimates were calculated using the 10th and 90th percentiles of the known country-level prevalence estimates from within the same sub-region. For countries where the best estimate was also presented with a range then these lower and upper estimates were incorporated into the 10th and 90th percentiles, respectively. The range reflects the sub-regional variability in prevalence estimates that were then applied to the population aged 15-64 from countries from within the same sub-region for which no country-level prevalence were available. By summing the upper and lower estimates for the number of PWID ranges in the regional and global estimates were calculated.

**People who inject drugs living with HIV (PWID PLHIV):**

**Best estimates:** Country-level estimates of the prevalence of PWID PLHIV were weighted by the number of PWID to obtain the sub-regional average. If the number of PWID was not known for a particular country with an PWID PLHIV estimate then the sub-regional average prevalence of PWID was used in the weighting. Countries within the same sub-region without a PWID PLHIV prevalence estimate were given the sub-regional average PWID PLHIV prevalence applied to number of PWID (known or sub-regional weighted average). The sub-regional numbers of PWID living with HIV were summed to obtain the regional and global estimates.

**Range in numbers of PWID PLHIV:** The range in the sub-regional estimates were calculated using the 10th and 90th percentiles of the known country-level prevalence estimates from within the same sub-region. For countries where the best estimate was also presented with a range then these lower and upper estimates were incorporated into the 10th and 90th percentiles, respectively. For each country a lower estimate of the number of PWID PLHIV was made using the lower estimate of the PWID PLHIV prevalence (either known or the sub-regional 10th percentile) and the lower estimate of the number of PWID (either known or sub-regional 10th percentile). The upper estimate was calculated in a similar manner using the upper estimate of PWID PLHIV prevalence and upper estimate of number of PWID. The estimated numbers of PWID PLHIV were summed to give regional and global lower and upper bounds to the number of PWID living with HIV.

**Review of data and methodology for PWID and those among them living with HIV**

In calculating the 2013 estimates, UNODC, UNAIDS, WHO and the World Bank joined forces and reached out to a broad group of experts from academia (including all former members of the Reference Group to the United Nations on HIV and Injecting Drug Use), regional, international and civil society organizations to ensure that a scientific approach to the methodology was used and to access the greatest number of data sets available worldwide on the subject. The new estimates reflect the results of the second joint UNODC/WHO/UNAIDS/World Bank data and methodology review.

**Data quality of estimates on injecting drug use and HIV among PWID**

**Interpretation of regional and global estimates**

The global and regional estimates of the prevalence of injecting drug use and HIV among people who inject drugs presented for 2013 in the World Drug Report should be viewed as an update to those presented in previous editions of the World Drug Report which reflects the latest data available. This year new or updated information was identified on PWID from 22 countries and on HIV among PWID from 51 countries. There is no intention to imply that there has been an actual change in the prevalence of injecting drug use or HIV among PWID at the regional or global level. The new values represent an update based on the best estimates that can currently be made using the most recent and highest quality data available to UNODC, WHO, UNAIDS, and the World Bank.

**Quality of national-level data on PWID**

Of the 93 countries with information on the prevalence of PWID, 62 per cent were of high methodological quality (class A, as defined in the table) and 75 per cent related to timely data from 2009 or more recently. Nearly a half (48 per cent) of the countries have information that is from recent, methodologically high quality surveys. With a low level of coverage of the population aged 15-64 compared to other regions there is limited information on PWID for countries in Africa. It is noticeable that there are no recent, methodologically high quality data from the Americas. However, for the two sub-regions with the highest prevalence of PWID (Eastern and South-Eastern Europe, and Central Asia and Transcaucasia) there is a very high percentage data coverage of the populations aged 15-64 and a high proportion of the data are both recent and of high methodological quality.

**Quality of national-level data on HIV among PWID**

Of the 114 countries with information on the prevalence of HIV among PWID, 62% were of high methodological quality (class A, as defined in the table) and 64% related to timely data from 2011 or more recently. More than a third (39%) of the countries have information that is from both recent and methodologically high quality surveys. In Latin America and the Caribbean there are no recent high quality studies on the prevalence of PWID (as outlined above) and only a very small proportion of the data available on the prevalence of HIV among PWID that is of recent, methodologically high quality. The Near and Middle East has no recent, methodologically high quality data, although the data that are available suggest a very low prevalence of injecting drug use and HIV among PWID. The two sub-regions that have by far the highest
10

and 73 countries on opioid substitution therapy. Syringe programmes, 49 countries on antiretroviral therapy. A total of 59 countries reported information on needle and syringe programmes, 49 countries on antiretroviral therapy.

Levels of service coverage for PWID and those among them living with HIV

Coverage of needle and syringe programmes refers to the percentage of all people who inject drugs who were reached by a needle and syringe programme over the past 12 months (low, < 25 per cent; medium, 25 - 50 per cent; high, > 50 per cent). Coverage of antiretroviral therapy refers to the percentage of all HIV positive people who inject drugs receiving antiretroviral therapy at a specified date (low, < 25 per cent; medium, 25 - 75 per cent; high, > 75 per cent). Coverage of opioid substitution therapy refers to the percentage of opioid-dependent people who inject drugs on opioid substitution therapy (low, < 20 per cent; medium, 20 - 40 per cent; high, > 40 per cent). A total of 59 countries reported information on needle and syringe programmes, 49 countries on antiretroviral therapy and 73 countries on opioid substitution therapy.

Drug-related deaths include those directly or indirectly caused by the intake of illicit drugs, but it may also include deaths where the use of illicit drugs was a contributory cause, including cases where drug use was involved in the circumstances of the deaths (for example, violence and traffic accidents). Member States report on drug-related deaths according to their own definitions and therefore care should be taken in making country comparisons.

The total number of drug-related deaths reported by Member States were used to determine a rate for the reporting year and this rate was used to produce an estimate of the number of drug-related deaths corresponding to the year 2013. The estimated number of drug-related deaths for 2013 were aggregated at the regional level. To account for non-responding countries, an upper and lower estimate of the number of deaths was made using the 10th and 90th percentiles of the mortality rates for countries that did report within the same region. In North America, all countries reported and therefore, no range was given. Because of the lack of reported information on drug-related deaths

<table>
<thead>
<tr>
<th>Region</th>
<th>Subregion</th>
<th>Percent coverage of population aged 15-64</th>
<th>Percent with recent data (2009 or more recent)</th>
<th>Percent with high methodological quality (class A)</th>
<th>Percent with recent and high methodological quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td></td>
<td>62</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Latin America and the Caribbean</td>
<td></td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Asia</td>
<td>Central Asia and Transcaucasia</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Europe</td>
<td>East and South-East Asia</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>South-West Asia</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Near and Middle East</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>South Asia</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Europe</td>
<td>Eastern and South-Eastern Europe</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Western and Central Europe</td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Oceania</td>
<td></td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td>61</td>
<td>33</td>
<td>67</td>
<td>52</td>
</tr>
</tbody>
</table>

Sources for original estimates on PWID: UNODC annual report questionnaire, progress reports of UNAIDS on the global AIDS response (various years), the former Reference Group to the United Nations on HIV and Injecting Drug Use and national government reports. Methodological quality is classified A – D1 (with A being the highest quality) according to a slightly modified classification originally proposed by Mathers et al., “Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.” The Lancet, Volume 372, Issue 9651, 1733 - 1745: A, Indirect prevalence estimation methods (e.g., capture-recapture, multiplier methods); B, General population survey; C, Treatment and other national registers of drug users; D1, - Official government estimate with no methodology reported. - Experts’ judgment with known method of estimation (e.g., an estimate obtained through a rapid assessment). - Delphi method or other consensus estimate.

The percentage of countries included in each category is graphically represented by a circle. A white circle indicating zero per cent, one quarter black indicates up to 25%, a half black circle between more than 25% and up to 50%, a three-quarter black circle between more than 50% and up to 75%, and a full black circle over 75% of the countries.

Prevalence of HIV among PWID (South-West Asia, and Eastern and South-Eastern Europe) have prevalence estimates from all countries and from recent methodologically high quality data sources from a good percentage of those countries.

Estimates of the number of drug-related deaths

Because of the lack of reported information on drug-related deaths
related deaths in Africa, an alternative source was used.\textsuperscript{3} The wide range in the estimates for Asia reflects the low level of reporting from countries in the region. The best estimate for Asia is placed towards the upper end of the reported range because a small number of highly populated countries reported a relatively high mortality rate, which produces a high regional average. The global estimate of the number of drug-related deaths is the sum of the regional estimates. The overall estimated number of deaths for a region was presented as a range to account for uncertainty, and also presented as a rate per 1 million population for a region was presented as a range to account for uncertainty, and also presented as a rate per 1 million population.

### Drug cultivation, production and manufacture

Data on cultivation of opium poppy and coca bush and production of opium and coca leaf for the main producing countries (Afghanistan, Myanmar and the Lao People’s Democratic Republic, for opium; and Colombia, Peru and the Plurinational State of Bolivia for coca) are mainly derived from national monitoring systems supported by UNODC in the framework of the Global Illicit Crop Monitoring Programme (ICMP). Estimates of cannabis cultivation in 2009, 2010, 2011 and 2012 in Afghanistan, as well as cannabis cultivation in 2003, 2004 and 2005 in Morocco, were also produced by the UNODC-supported national monitoring systems. Estimates for other countries were drawn from ARQ replies and various other sources, including reports from Governments, UNODC field offices and the United States Department of State’s Bureau for International Narcotics and Law Enforcement Affairs. Opium poppy cultivation in countries which do not conduct area surveys, was estimated with an indirect method (see below).

---

A full technical description of the methods used by UNODC-supported national monitoring systems can be found in the respective national survey reports available at http://www.unodc.org/unodc/en/crop-monitoring/index.html.

Net cultivation

Not all the fields on which illicit crops are planted are actually harvested and contribute to drug production. For Afghanistan, a system of monitoring opium poppy eradication is in place which provides all necessary information to calculate the net cultivation area. In Myanmar and the Lao People’s Democratic Republic, only the area of opium poppy eradicated before the annual opium survey is taken into account for the estimation of the cultivation area. Not enough information is available to consider eradication carried out after the time of the annual opium survey.

A major difference between coca and other narcotic plants such as opium poppy and cannabis is that the coca bush is a perennial plant which can be harvested several times per year. This longevity of the coca plant should, in principle, make it easier to measure the area under coca cultivation. In reality, the area under coca cultivation is dynamic which makes it difficult to determine the exact amount of land under coca cultivation at any specific point in time or within a given year. There are several reasons why coca cultivation is so dynamic, including new plantation, abandonment, reactivation of previously abandoned fields, manual eradication and aerial spraying.

The issue of different area concepts and data sources used to monitor illicit coca bush cultivation continues to be investigated by UNODC. To improve the comparability of estimates between countries, since 2011 net coca cultivation area at 31 of December is presented not only for Colombia but also for Peru. For technical reasons, the initial area measurement of coca fields takes place on satellite images acquired at different dates of the year and sometimes having different technical specifications. For the Bolivian and Peruvian estimate, these differences are considered to have a limited effect only, whereas the dynamic situation in Colombia requires adjustment to maintain year-on-year comparability. The Colombia coca cultivation series includes adjustments for small fields since 2009 while previous years did not require adjustment. For more details, please see the country specific reports.

Indirect estimation of illicit opium poppy cultivation

Eradication and plant seizure reports indicate that illicit opium poppy cultivation exists in many countries, which do not regularly conduct illicit crop surveys. Starting 2008 a new methodology was introduced to estimate the extent of this illicit cultivation with an indirect method based on two indicators available in UNODC’s databases: eradicated poppy area and opium poppy (plant, capsule) seizures reported as units or weight.

Prioritization of data sources: Whenever possible, the eradicated poppy area was used as this indicator is conceptually closest. If this indicator was not available, poppy plant seizure data was used, which requires an additional conversion of the seized amount into area eradicated. It can be assumed that plant seizures are often a different way of recording eradication, e.g. in cases where area measurements are technically difficult or because the law requires all seized material to be weighed even if the seizure consist actually of eradicating plants on a field. Large-scale or long-distance illicit trade with opium poppy plants is unlikely as the plants are bulky, perishable and of low value.

Eradication factor: Evidence from countries which provide both illicit cultivation and eradication data indicates that illicit cultivation is typically a multiple of the area eradicated. This relationship, averaged over the last five years for which information is available, was used to calculate a factor which allowed to estimate illicit cultivation in countries from eradication figures. Since 2008, this factor is based on opium poppy cultivation and eradication data from Colombia, Lao People’s Republic, Mexico, Myanmar, Pakistan and Thailand. It ranged between 2.1 and 3.0 (eradicated area x factor = net cultivation area). Afghanistan was not considered for the calculation of the factor as the objective was to estimate low to mid-levels of illicit cultivation. Afghanistan, representing two thirds or more of global illicit poppy cultivation, clearly fell outside this range.

Plant seizures: seizures of poppy plant material usually happen close to the source, i.e. in vicinity of the cultivation area. The data available in UNODC’s databases does not allow to determine the parts of the plant seized as only one category exists (“plant, capsules”) for plant seizures. Most (roots, stem, leaves, capsules) or only some parts (poppy straw, capsules only) may be seized. While this does not influence seizure data given as weight, it plays a role when interpreting seizure data given as weight.

Plant seizure data in units represent plant numbers, which can be converted into area (ha) using an average number of opium poppy plants per hectare. Yield measurements from Afghanistan and Myanmar, where UNODC has conducted yield surveys over several years, indicate an average figure of about 190,000 plants per hectare. Dividing poppy plant seizure numbers by this factor results in estimate of the area on which the seized material was cultivated. This is equivalent to eradicated area, as the seized material was taken out of the production cycle. Eradicated area multiplied with the eradication factor described above yields then cultivation area.

Plant seizure data reported as weight: In order to convert
the weight of seized poppy plants into area, a typical biomass per hectare of poppy was estimated based on the evaluation of various sources. The biomass yield in oven-dry equivalent including stem, leaves, capsule and seeds reported by a commercial licit opium poppy grower in Spain\(^6\) was 2,800 kg/ha for rain-fed and 7,200 kg/ha for irrigated fields respectively. Information on the weight of roots was not available. Loewe\(^7\) found biomass yields between 3,921 kg/ha to 5,438 kg/ha in trial cultivation under greenhouse conditions. Acock et al.\(^8\) found oven-dry plant weights of about 37 grams including roots in trials under controlled conditions corresponding to a biomass yield of around 7,000 kg/ha with the assumed plant density of 190,000/ha. Among the available biomass measurements only the figures from Spain referred to poppy grown under field conditions. All other results fell into the range between the non-irrigated and irrigated biomass yields (2,800 – 7,200 kg/ha) reported. For purposes of this calculation the simple average of these two values was taken.

Two caveats have to be made: a) As the reporting format does not differentiate between capsules and plants or between the different growth stages of a poppy plant, it was assumed that the reported weight refers to whole, mature plants. This leads to a conservative estimate as many plant seizures are actually carried out on fields before the poppy plants reach maturity. b) The reference biomass measurements from scientific studies are expressed in oven-dried equivalents, whereas the reported weights could refer to fresh weight or air-dry weight; both of which are higher than the oven-dry equivalent weight equivalent. This would lead to an over-estimation of the illicit cultivation area. In the case of young plants, which are typically fresh but not yet fully grown, both errors could balance off, whereas in the case of mature or harvested plants, which tend to be drier, both errors would be smaller.

**Missing values:** Not all states with illicit opium poppy cultivation report eradication or plant seizures on a yearly basis. If values were missing, the value used for that specific year was the average of the last 5 years. If no eradication or plant seizure was reported in that period, no value was taken.

**Yield\(^9\) and production**

To estimate the potential production of opium, cannabis (herb and resin), the number of harvests per year and the total yield of primary plant material has to be established. The UNODC-supported national surveys take measurements in the field and conduct interviews with farmers, using results from both to produce the final data on yield.

Opium yield surveys are complex. Harvesting opium with the traditional lancing method can take up to two weeks as the opium latex that oozes out of the poppy capsule has to dry before harvesters can scrape it off and several lancing takes place until the plant has dried. To avoid this lengthy process, yield surveyors measure the number of poppy capsules and their size in sample plots. Using a scientifically developed formula, the measured poppy capsule volume indicates how much opium gum each plant potentially yields. Thus, the per hectare opium yield can be estimated. Different formulas were developed for South-East and South-West Asia. In Afghanistan, Myanmar and Lao PDR, yield surveys are carried out annually.

For coca bush, the number of harvests varies, as does the yield per harvest. In the Plurinational State of Bolivia and Peru, UNODC supports monitoring systems that conduct coca leaf yield surveys in several regions, by harvesting sample plots of coca fields over the course of a year, at points in time indicated by the coca farmer. In these two countries, yield surveys are carried out only occasionally, due to the difficult security situation in many coca regions and because of funding constraints. In Colombia, coca leaf yield estimates are updated yearly through a rotational monitoring system introduced in 2005 that ensures that every yield region is revisited about every three years. However, as the security situation does not allow for surveyors to return to the sample fields, only one harvest is measured, and the others are estimated based on information from the farmer. In 2013 for the first time the concept of productive area was applied to calculate the coca leaf yields in Colombia, taking into account the dynamics of the fields due to spraying and eradication for which some fields are only partly productive during the year. This new way of calculating was retroactively applied to the results of 2009-2012, giving slightly different results than published before\(^10\). Also in Peru the coca leaf yield figures for 2013 were calculated in a different manner applying a correction factor for the time that fields were productive during the year. This new calculation was only applied to the 2013 estimates.\(^11\)

**Conversion factors**

---

6 Personal communication, 2010, from Alcaliber company.
9 Further information on the methodology of opium and coca leaf yield surveys conducted by UNODC can be found in United Nations (2001): Guidelines for Yield Assessment of Opium Gum and Coca Leaf from Brief Field Visits, New York (ST/NAR/33).
The primary plant material harvested - opium in the form of gum or latex from opium poppy, coca leaves from coca bush, and the cannabis plant - undergo a sequence of extraction and transformation processes, some of which are done by farmers onsite, others by traffickers in clandestine laboratories. Some of these processes involve precursor chemicals and may be done by different people in different places under a variety of conditions, which are not always known. In the case of opium gum, for example, traffickers extract the morphine contained in the gum in one process, transform the morphine into heroin base in a second process, and finally produce heroin hydrochloride. In the case of coca, coca paste is produced from either sun-dried (in the Plurinational State of Bolivia and Peru) or fresh coca leaves (in Colombia), which is later transformed into cocaine base, from where cocaine hydrochloride is produced.

The results of each step, for example, from coca leaf to coca paste, can be estimated with a conversion factor. Such conversion factors are based on interviews with the people involved in the process, such as farmers in Colombia, who report how much coca leaf they need to produce 1 kg of coca paste or cocaine base. Tests have also been conducted where so-called ‘cooks’ or ‘chemists’ demonstrate how they do the processing under local conditions. A number of studies conducted by enforcement agencies in the main drug-producing countries have provided the orders of magnitude for the transformation from the raw material to the end product. This information is usually based on just a few case studies, however, which are not necessarily representative of the entire production process. Farmer interviews are not always possible due to the sensitivity of the topic, especially if the processing is done by specialists and not by the farmers themselves. Establishing conversion ratios is complicated by the fact that traffickers may not know the quality of the raw material and chemicals they use, which may vary considerably; they may have to use a range of chemicals for the same purpose depending, on their availability and costs; and the conditions under which the processing takes place (temperature, humidity, et cetera) differ.

It is important to take into account the fact that the margins of error of these conversion ratios – used to calculate the potential cocaine production from coca leaf or the heroin production from opium - are not known. To be precise, these calculations would require detailed information on the morphine content of opium or the cocaine content of the coca leaf, as well as detailed information on the efficiency of clandestine laboratories. Such information is limited. This also applies to the question of the psychoactive content of the narcotic plants.

UNODC, in cooperation with Member States, continues to review coca leaf to cocaine conversion ratios as well as coca leaf yields and net productive area estimates. More research is needed to establish comparable data for all components of the cocaine production estimate.

Many cannabis farmers in Afghanistan and Morocco conduct the first processing steps themselves, either by removing the upper leaves and flowers of the plant to produce cannabis herb or by threshing and sieving the plant material to extract the cannabis resin. The herb and resin yield per hectare can be obtained by multiplying the plant material yield with an extraction factor. The complex area of cannabis resin yield in Afghanistan was investigated in 2009, 2010, 2011 and 2012. The yield study included observation of the actual production of resin, which is a process of threshing and sieving the dried cannabis plants. In Morocco, this factor was established by using information from farmers on the methods used and on results from scientific laboratories. Information on the yield was obtained from interviews with cannabis farmers. Given the high level of uncertainty and the continuing lack of information in many cannabis-cultivating countries, the estimate of global cannabis herb and resin production have not been calculated.

Potential production

‘Potential’ heroin or cocaine production shows the total production of heroin or cocaine if all the cultivated opium or coca leaf were transformed into the end products in the respective producer country in the same year. However, part of the opium poppy or coca leaf itself is directly consumed in the producing countries or in neighbouring countries. In addition, significant quantities of the intermediate products, coca paste or morphine, are also consumed in the producing countries. Some products such as opium can be stored for extended periods of time and be converted into intermediate or final products long after the harvest year. These factors are partly taken into account: for example, consumption of coca leaf considered licit in the Plurinational State of Bolivia and Peru is not taken into account for the transformation into cocaine. Other factors, such as the actual amount of illicit coca paste or opium consumption and storage, are difficult to estimate and were not taken into account.

For cocaine, potential production of 100% pure cocaine is estimated. In reality, clandestine laboratories do not produce 100% pure cocaine but cocaine of lower purity which is often referred to as ‘export quality’. For heroin, two conversion ratios are used. Apart from Afghanistan, not enough information is available to estimate the production of heroin of 100% purity. Instead, potential production of export quality heroin is estimated, whose exact purity is not known and may vary. For Afghanistan, the calculations are more detailed, here the share of all opium converted to heroin is estimated and a specific conversion factor was presented in the 2010 World Drug Report, p.251 ff.
ratio is applied, which uses an estimated purity for heroin of export quality.

Although it is based on current knowledge on the alkaloid content of narcotic plants and the efficiency of clandestine laboratories, ‘potential production’ is a hypothetical concept and is not an estimate of actual heroin or cocaine production at the country or global level. The concept of potential production is different from the theoretical maximum amount of drug that could be produced if all alkaloids were extracted from opium and coca leaf. The difference between the theoretical maximum and the potential production is expressed by the so-called laboratory efficiency, which describes which proportion of alkaloids present in plant material clandestine laboratories are actually able to extract.

**Colombia**

In 2013, for the first time, the yearly productive area was estimated, instead of using the average area under coca cultivation of the reporting year and the previous year. In addition a different conversion factor for estimating cocaine base was applied. Both the adjustment of the productive area estimate and the estimation of the conversion factor for cocaine base were retroactively applied to the results of 2009–2012, giving slightly different results than published before.14

**Peru**

Potential cocaine production in Peru is estimated from potential coca leaf production (in 2013 for the first time adjusted for eradication) and after deducting the amount of coca leaf estimated to be used for traditional purposes according to Government sources (9,000 mt of sun-dry coca leaf).

**The Plurinational State of Bolivia**

Potential cocaine production in the Plurinational State of Bolivia is estimated from potential coca leaf production after deducting the amount of coca leaf produced on 12,000 ha in the Yungas of La Paz where coca cultivation is authorized under national law.

**Drug trafficking**

**Seizures**

The analysis presented in this report is mainly derived from the ARQ responses from Member States up to the 2013 reporting year. Including information from other sources, UNODC was able to obtain seizure data from 129 countries and territories for 2013. Seizures are the most comprehensive indicator of the drug situation and its evolution at the global level. Although seizures may not always reflect trafficking trends correctly at the national level, they tend to show reasonable representations of trends at the regional and global levels.

Countries may report seizures of drugs using a variety of units, primarily by weight (kg) but also in litres, tablets, doses, blotters, capsules, ampoules, et cetera. When reporting about individual countries in individual years, UNODC endeavours to be as faithful as possible to the reports received, but often it is necessary to aggregate data of different types for the purposes of comparison. For the aggregation, conversion factors are used to convert the quantities into ‘kilogram equivalents’ (or ‘ton equivalents’). UNODC continues to record and report the disaggregated raw data, which are available in the seizure listings published at: [http://www.unodc.org/unodc/en/data-and-analysis/WDR.html](http://www.unodc.org/unodc/en/data-and-analysis/WDR.html) In these tables, seizure quantities are reproduced as reported. In the rest of the Report, seizure data are often aggregated and transformed into this unique unit of measurement. Moreover, at some points in the analysis, purity adjustments are made where relevant and where the availability of data allows.

The conversion factors affect seizure totals of amphetamine-type stimulants in particular, as a significant share of seizures of these drug types is reported in terms of the number of tablets. Apart from seizures of ATS tablets, drug seizures are mainly reported to UNODC by weight, and sometimes by volume. This includes seizures of ATS which are not seized in tablet form (for example, ATS in powder, crystalline or liquid form) as well as seizures of other drug types, such as heroin and cocaine. Moreover, ATS seizures made in tablet form are also sometimes reported by weight, and in some cases, the reported total aggregated weight possibly includes ATS seized in different forms. Reports of seizures by weight usually refer to the bulk weight of seizures, including adulterants and diluents, rather than the amount of controlled substance. Moreover, given the availability of data, accurate purity adjustments for bulk seizure totals in individual countries are feasible in a minority of cases, as they would require information on purity on a case by case basis or statistically calibrated data, such as a weighted average or a distribution. The bulk weight of tablets is easier to obtain and less variable.

To ensure the comparability of seizure totals across different years and countries, UNODC uses conversion factors for ATS tablets intended to reflect the bulk weight of the tablets rather than the amount of controlled substance. The factors used in this edition of the *World Drug Report* are based on available forensic studies and range between 90 mg and 300 mg, depending on the region and the drug type, and also apply to other units which are presumed to represent a single consumption unit (dose). The table below lists the factors used for ‘ecstasy’, amphetamine, methamphetamine, and non-specified ATS. The conversion factors remain subject to revision as the information available to UNODC improves.

---

For the other drug types, the weight of a ‘typical consumption unit’ was assumed to be: for cannabis herb, 0.5 g; for cannabis resin, 0.135 g; cocaine and morphine, 0.1 g; heroin, 0.03 g; LSD, 0.00005 g (50 micrograms); and opium, 0.3 g. For opiate seizures (unless specified differently in the text), it was assumed that 10 kg of opium were equivalent to 1 kg of morphine or heroin. Though these transformation ratios can be disputed, they provide a means of combining the different seizure reports into one comprehensive measure. The transformation ratios have been derived from those normally used by law enforcement agencies, in the scientific literature and by the International Narcotics Control Board, and were established in consultation with UNODC’s Laboratory and Scientific Section. As in previous editions of the World Drug Report, seizures quantified by volume (litres) are aggregated using a conversion ratio of 1 kilogram per litre, which applies to all drug types. Cannabis plants are assumed to have a weight of 100 grams.

**Trafficing routes and volumes**

Information of trafficing routes was mainly obtained from analyses of individual drug seizures reported to UNODC, as well as analyses of trafficing routes reported by Member States.

Information provided on the main transit countries reported in individual drug seizure cases are as follows. Analysis of cases for which provenance was reported: 11,441 cases of cannabis, 11,864 cases of cocaine and 4,041 cases of heroin. Reporting countries are asked to provide information on the country where the drugs were obtained (or, in the case of unaccompanied shipments, the departure country). For the purposes of Table 5 (page 40) in the World Drug Report 2015, this is considered as the last departure (in most cases in transit) of the drug shipment. In order to reflect patterns in transnational trafficing, any cases where the last departure point coincides with the destination were excluded. The figures provided in Table 5 in the World Drug Report 2015 refer to the total number of mentions of the country as the last departure/transit point in individual seizure cases reported to the UNODC over the 10-year period 2005-2014, and to the number of different reporting countries responsible for those mentions. It should be noted that some major consuming countries did not report on transit and departure countries.

**Market analysis**

**Drug price and purity data**

Price and purity data, if properly collected and reported, can be powerful indicators of market trends. Trends in supply can change over a shorter period of time when compared with changes in demand and shifts in prices and purities are relatively good indicators for increases or declines of market supply. Research has shown that short-term changes in the consumer markets are first reflected in purity changes while prices tend to be rather stable over longer periods of time. UNODC collects its price data from the ARQ, and supplements this data with other sources such as DAINAP, EMCDDA and Government reports. Prices are collected at farm-gate level, wholesale level (‘kilogram prices’) and at retail level (‘gram prices’). Countries are asked to provide minimum, maximum and typical prices and purities. When countries do not provide typical prices/purities, for the purposes of certain estimates, the mid-point of these estimates is calculated as a proxy for the ‘typical’ prices/purities (unless scientific studies are available which provide better estimates). What is generally not known is how data were collected and how reliable it is. Although improvements have been made in some countries over the years, a number of law enforcement bodies have not yet established a regular system for collecting purity and price data.

Prices are collected in local currency but are often converted into US dollars for the purposes of comparability among countries. The conversion into US dollars is based on official UN rates of exchange for the year. However, comparisons of prices from different years need to be made with caution as they are influenced by changes in the
exchange rates and may not necessarily reflect changes in the local markets.

**New Psychoactive Substances**

The main data source for new psychoactive substances (NPS) in the World Drug Report is the UNODC Early Warning Advisory on New Psychoactive Substances (www.unodc.org/nps). This monitoring mechanism compiles information on the emergence of NPS by substance, year and country mainly from a network of forensic laboratories, UNODC questionnaire surveys on NPS, EMCDDA and the ARQ.

**Methodology for section on Drug Prevention**

The section reviews and presents scientific evidence on the effectiveness of drug prevention. The main document on which this section is based is the International Standards of Drug Prevention published in 2013 by UNODC. The methodology of how the evidence was searched, selected, extracted and finally assessed is described in detail in Appendix II of the document. To make sure that more recent research findings were considered for the conclusions the literature base was extended to more recent systematic reviews systematically searched in the framework of an extensive international report on effectiveness of substance abuse prevention (Bühler & Thrul, 2013). In addition, relevant single studies were included in the section to illustrate potential effects of specific prevention approaches.

**Reviews included in the section**

General conclusions about the effectiveness of specific prevention approaches were drawn from reviews referred to in the text, which summarize the results of many single studies. In both reference documents, the UNODC Standards (2013) and Bühler & Thrul (2013), following established scientific protocols, a systematic search and collection strategy in scientific data bases was implemented to rule out biased selection of publications. In addition to this, for the Standards, a group of leading international experts in prevention who participated in the writing process were asked to name relevant studies.

Quality of reviews was also rated in both documents mainly taking into account (a) how transparent and systematic their search strategy for single studies was, (b) what kind of quality level the single studies included had (see below) and (c) whether the results of the single studies were integrated qualitatively or quantitatively.

Both documents’ approaches of study selection and assessment are seen to assure that the evidence base includes all the most important studies and that the studies are of sufficient quality. The evidence level varies substantially between settings and approaches. Following principles of evidence-based practice, it was referred to the best available scientific knowledge.

**Single studies included in the section**

To demonstrate the potential impact of specific effective approaches, results of high-quality single efficacy studies are presented in the section. High-quality is indicated by the utilization of research methods to eliminate alternative explanations of intervention effects, e.g. use of intervention and control group, randomized assignment to groups,
multivariate statistics, long-term follow up.

Starting with the conclusion reported in the text, the primary studies quoted by the review supporting the conclusion were screened. The primary study was chosen which had highest methodological quality and presented results communicable to non-statisticians. It was then checked whether a more recent study paper was published relying on the Pubmed Database. Study results were then presented as figures indicating difference in outcomes between intervention and control group.

ALTERNATIVE DEVELOPMENT

B. SETTING THE SCENE

Geographical location of alternative development

A total of 23 countries reported to UNODC in their replies to the Annual Reports Questionnaire that they implemented alternative development programmes during the period 2010-2013. If countries were added which were reported in OECD’s “Creditor Reporting System - Aid Activity database” to have been ‘beneficiaries’ of alternative development committed by OECD countries over the 1998-2013 period, the total would rise to 93 countries, i.e. about half of the overall number of UN member states (193). Two thirds (60 countries) of these countries received, however, less than US$ 100,000 per year (range: US$ 120-US$ 100,000 per year). This makes it questionable whether such small financial flows were in fact linked to efforts to prevent illicit drug production. Such minor recipients were thus excluded from the recipient countries shown in Map 2 of the report. Nonetheless, similar doubts also hold true for some of the other countries, notably countries in central and eastern Africa, which received slightly higher funds but are unlikely to have been actively involved in significant alternative development efforts linked to drug control efforts.

F. STRATEGIC ELEMENTS OF ALTERNATIVE DEVELOPMENT PROGRAMMES

For the preparation of the chapter on Alternative Development, UNODC conducted a survey among alternative development experts between December 2014 and February 2015. Twenty-five experts replied, including alternative development policy experts (41 per cent), general drug policy experts (22 per cent), development experts (22 per cent) and field researchers (7 per cent). Most of those experts were working with international organizations (33 per cent) or governments (26 per cent) while others were employed by NGOs (19 per cent) or the private sector (19 per cent). The majority of respondents had experience of alternative development activities in Latin America (65 per cent), others in South-East Asia (20 per cent), South-West Asia (13 per cent) and Africa (one expert). Selected survey findings have been incorporated in section F. Strategic elements of alternative development programmes, and G. Measuring the success of alternative development of chapter 2. A summary of the findings is included in the online Annex of the World Drug Report.

H. POINTS OF FUTURE INTEREST

Impact of illicit drug production and alternative development interventions

The economic value of illicit crop cultivation can be far more significant for the local communities living in the main opium and coca producing areas. For example, the province of Helmand in Afghanistan holds just 3.4 per cent of the country’s total population but accounts for close to 50 per cent of Afghanistan’s total area under opium poppy cultivation (48 per cent in 2013). Based on UNODC’s annual opium poppy survey, about 27 per cent of the total agriculture area in this province was under opium poppy cultivation in 2013 while the farm-gate value of opium production in this province may have reached more than a third of the province’s licit GDP.

The latter proportion is only a tentative estimate as no official GDP data at the provincial level are available. However, based on survey data, some information on the provincial breakdown of national per capita expenditure exists. This may be used as a proxy for the regional GDP breakdown as such private consumption accounts for the bulk of total GDP in Afghanistan (on average 89 per cent of overall GDP over the Afghan Calendar years 1388-1392, i.e. the period 2009/2010-2013/14). Published data on “mean expenditure per person per month” (Islamic Republic of Afghanistan, Afghanistan Drug Report 2012, Kabul 2013, based on Central Statistical Office, Statistical Yearbook 2007-2008) suggest, in combination with detailed population estimates, that Helmand province accounts for 5 per cent of total national expenditures. Applying this proportion to the national GDP (US$ 21.04 billion in 2013) would give a provincial GDP of around US$ 1.05 billion for the province of Helmand for the year 2013. The area under opium poppy cultivation in Helmand province amounted to 100,700 ha in 2013. Multiplied with the average opium yield in this region, opium production in Helmand province was estimated at US$ 2,339 tons in 2013. This production figure, multiplied with the regional opium farm-gate price (US$ 161 per kg), results in an estimate of the farm-gate value of Helmand opium production of some US$ 377 million in 2013. Thus opium production accounts for 40 per cent of Afghanistan’s overall opium farmgate value (US$950 million) and it would be equivalent to around 36 per cent - and thus more than a third - of Helmand’s estimated GDP in 2013.